Walter V. Klemp - Jul 11, 2023 Form 4 Insider Report for Moleculin Biotech, Inc. (MBRX)

Role: CEO and President, Director
Signature: /s/ Jonathan P. Foster by Power of Attorney
Stock symbol: MBRX
Transactions as of: Jul 11, 2023
Transactions value $: -$1,898
Form type: 4
Date filed: 7/13/2023, 06:35 PM
Previous filing: Jul 5, 2023
Next filing: Dec 27, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MBRX	Common Stock	Options Exercise		+13.2K	+2.74%		496K	Jul 11, 2023	Direct	F1
transaction	MBRX	Common Stock	Tax liability	-$1.9K	-3.22K	-0.65%	$0.59	492K	Jul 11, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MBRX	Restricted Stock Units	Options Exercise	$0	-13.2K	-0.68%	$0.00	1.93M	Jul 11, 2023	Common Stock	13.2K		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert into common stock on a one-for-one basis.
F2	Shares withheld for payment of taxes upon vesting of restricted stock unit awards.
F3	On July 11, 2019, the reporting person was granted 52,818 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.